These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 9263656

  • 1. Antiplatelet and antithrombin therapies in the acute coronary syndromes.
    Alexander JH, Harrington RA.
    Curr Opin Cardiol; 1997 Jul; 12(4):427-37. PubMed ID: 9263656
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antiplatelet agents in acute coronary syndromes.
    Eikelboom JW, Anand S.
    Semin Vasc Med; 2003 Nov; 3(4):403-14. PubMed ID: 15199447
    [Abstract] [Full Text] [Related]

  • 5. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Glycoprotein 2b3a inhibitors for acute coronary syndromes: what the trials tell us].
    Elian D, Guetta V.
    Harefuah; 2003 May; 142(5):350-4, 398. PubMed ID: 12803058
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ, Guzman LA, Bass TA.
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [Abstract] [Full Text] [Related]

  • 11. Prevention of cardiovascular events after acute coronary syndrome.
    Wallentin L.
    Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Use of platelet antiaggregating agents in acute coronary syndromes].
    Torres Peláez Mde L, Santiago Arana C.
    Arch Cardiol Mex; 2002 Aug; 72 Suppl 1():S291-5. PubMed ID: 12001865
    [Abstract] [Full Text] [Related]

  • 15. New strategies in the management of acute coronary syndromes.
    Fullwood J, Butler G, Smith T, Cox M, Bride W, Mostaghimi Z, Cook PS, Granger BB.
    Nurs Clin North Am; 2000 Dec; 35(4):877-95. PubMed ID: 11072276
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition.
    Ferguson JJ, Waly HM, Wilson JM.
    Eur Heart J; 1998 Apr; 19 Suppl D():D3-9. PubMed ID: 9597517
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.